Biocytogen Pharmaceuticals Secures Japan Patent for RenMab Platform, Expanding Global Patent Portfolio

Reuters
05 Jun
Biocytogen Pharmaceuticals Secures Japan Patent for RenMab Platform, Expanding Global Patent Portfolio

Biocytogen Pharmaceuticals has announced that its RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office. This achievement marks a significant advancement in the company's global intellectual property strategy, strengthening the patent portfolio for its RenMice® fully human antibody platform. The patent underscores Biocytogen's commitment to innovation and international recognition of its proprietary technologies. The RenMice platform continues to demonstrate strong global competitiveness, with approximately 200 agreements executed for therapeutic antibody co-development and out-licensing as of December 31, 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocytogen Pharmaceuticals Beijing Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10